Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 4/3/2024 | $6.00 | Hold → Buy | Maxim Group |
| 11/1/2022 | $18.00 | Buy | Loop Capital |
| 11/30/2021 | $25.00 | Buy | Maxim Group |
| 11/22/2021 | $40.00 → $50.00 | Buy | HC Wainwright & Co. |
| 11/16/2021 | $25.00 → $24.00 | Outperform | Credit Suisse |
| 11/16/2021 | $19.00 → $17.00 | Sector Perform | RBC Capital |
| 11/11/2021 | $32.00 | Buy | Roth Capital |
| 10/18/2021 | $40.00 | Buy | HC Wainwright & Co. |
NEW YORK and BERLIN, Oct. 15, 2024 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ:ATAI) ("atai" or "Company"), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today announced that Srinivas Rao, M.D., Ph.D., the Company's Co-founder and Co-CEO, is scheduled to participate in the 2024 Maxim Healthcare Virtual Summit taking place from October 15 – 17, 2024. Details of the company's participation: Format: Virtual fireside chat Date: Wednesday, October 16, 2024 Presentation Time: 3:30 P.M. EDTWebcast: Register here An archived replay will be available on the Investors section of the atai website under Events for up to 30 days. About at
NEW YORK and BERLIN, Sept. 04, 2024 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ:ATAI) ("atai" or "Company"), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today announced that the Company's management team is scheduled to participate in the H.C. Wainwright 26th Annual Global Investment Conference in New York, NY from September 9-11, 2024. Details of the company's participation: Format: Fireside chat and 1x1 investor meetingsDate and Time: Fireside chat on Tuesday, September 10 at 4:30 P.M. EDTWebcast link: Here An archived replay will be available on the Investors section of the atai website under Events for up to 90 days. Ab
• Reported positive Phase 1b results of VLS-01 (buccal film DMT); expect to initiate a Phase 2 study in treatment-resistant depression patients around YE'24 • Announced clinical development plans for EMP-01 (oral R-MDMA); expect to initiate a Phase 2 study of EMP-01 in social anxiety disorder patients around YE'24 • Cash, marketable securities, and committed term loan funding expected to fund operations into 2026 NEW YORK and BERLIN, Aug. 13, 2024 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ:ATAI) ("atai" or "Company"), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today announced second quarter 2024 financial results and pr
8-K - ATAI Life Sciences N.V. (0001840904) (Filer)
8-K - ATAI Life Sciences N.V. (0001840904) (Filer)
10-Q - ATAI Life Sciences N.V. (0001840904) (Filer)
NEW YORK and BERLIN, May 23, 2024 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ:ATAI) ("atai" or "Company"), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today announced the appointment of Scott Braunstein, M.D., and Laurent Fischer, M.D., as independent directors of atai's supervisory board ("Board") subject to applicable legal requirements. Scott Braunstein, M.D., is the Chief Executive Officer ("CEO") and Chairman of Marinus Pharmaceuticals, Inc. He is an operating partner at Aisling Capital and serves on the Board of Directors at both Caribou Biosciences, Inc. and Trevena Inc. Previously, Dr. Braunstein was Chief Operati
NEW YORK and BERLIN, Feb. 06, 2024 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ:ATAI) ("atai" or "Company") today announced that Anne Johnson, the Company's interim Chief Financial Officer since October 2023 and Chief Accounting Officer since August 2022, has been named Chief Financial Officer (CFO). Anne succeeds Stephen Bardin as the Company's CFO while Stephen will continue in an advisory role until March 31, 2024 to support the transition. "Anne has been an integral member of our team for over three years and has demonstrated the executive leadership, financial acumen, and track record to lead our financial organization with excellence," said atai Co-founder and Chief Executive Off
Cognito Therapeutics, a pioneer developing disease-modifying therapeutics to treat CNS diseases, today announced the appointment of Greg Weaver as Chief Financial Officer (CFO), to lead all finance-related and investor relations functions at the Company. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231017630946/en/Greg Weaver, CFO, Cognito Therapeutics (Photo: Business Wire) Mr. Weaver is a highly accomplished finance executive who brings more than 30 years of life sciences, financial and operations experience to Cognito. Most recently, he served as CFO of Atossa Therapeutics, Inc. (NASDAQ:ATOS), a clinical-stage oncology comp
4 - ATAI Life Sciences N.V. (0001840904) (Issuer)
4 - ATAI Life Sciences N.V. (0001840904) (Issuer)
4 - ATAI Life Sciences N.V. (0001840904) (Issuer)
Maxim Group upgraded atai Life Sciences N.V. from Hold to Buy and set a new price target of $6.00
Loop Capital initiated coverage of atai Life Sciences N.V. with a rating of Buy and set a new price target of $18.00
Maxim Group initiated coverage of atai Life Sciences N.V. with a rating of Buy and set a new price target of $25.00
4 - ATAI Life Sciences N.V. (0001840904) (Issuer)
Strategic investment in Beckley Psytech reinforces atai's position as the biopharmaceutical company with the largest and most diverse portfolio of clinical-stage psychedelic candidatesTwo patent-protected, clinical-stage programs BPL-003 (intranasal 5-MeO-DMT) and ELE-101 (intravenous psilocin) complement atai's existing drug development programs Multiple clinical readouts anticipated from this investment in Beckley Psytech within next 12 months, including a Phase 2b readout of BPL-003 in Treatment Resistant Depression in 2H24 BPL-003 has the potential to become a first-in-class short-duration psychedelic treatment with rapid acting and durable antidepressant effects Anticipated synergies th
– Highlights included positive Phase 2b data with COMP360 from a ground-breaking treatment resistant depression (TRD) trial, highly encouraging Phase 2a proof-of-mechanism data with RL-007 in cognitive impairment associated with schizophrenia (CIAS), clinical trial initiations with PCN-101, GRX-917 and DMX-1002, and successful completion of 2 cohorts in the Introspect Digital Therapeutics ketamine trials – Eight new programs added to platform since January 2021 bringing total, as of today, to 13 discovery and drug development programs and four enabling technologies – Ended 2021 very well capitalized with $362 million to execute our strategy to achieve clinically meaningful and sustai
NEW YORK and BERLIN, March 23, 2022 (GLOBE NEWSWIRE) -- atai Life Sciences N.V. (NASDAQ:ATAI) ("atai"), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today announced that it plans to host a webcast on Wednesday, March 30, 2022 at 8:30 a.m. ET to discuss its financial results for the fourth quarter 2021 and provide a business update. To access the webcast, please log in at https://wsw.com/webcast/cc/atai/1358298. The live and archived webcast of this call will be available in the "Events" section of the atai Life Sciences website at ir.atai.life. About atai Life Sciences atai was founded in 2018 as a response to the significant
SC 13D/A - ATAI Life Sciences N.V. (0001840904) (Filed by)
SC 13D/A - ATAI Life Sciences N.V. (0001840904) (Filed by)
SC 13D/A - ATAI Life Sciences N.V. (0001840904) (Filed by)
Cantor Fitzgerald analyst Charles Duncan reiterates ATAI Life Sciences (NASDAQ:ATAI) with a Overweight.
ELE-101 is a patent-protected, synthetic formulation of psilocin, designed to offer the therapeutic benefits of psilocybin in a more consistent, controllable, and shorter treatment paradigm of approximately two hours. The Phase 2a part of the study will evaluate the safety, tolerability, subjective effects, and efficacy of a single intravenous (IV) dose of ELE-101 in 6-12 participants with Major Depressive Disorder (MDD). Results are expected in H2 2024. The dose for Phase 2a was selected using preliminary pharmacokinetic (PK) and pharmacodynamic (PD) data from the Phase 1 randomized, double-blind, placebo-controlled, single ascending dose part of the study of ELE-101 in healthy particip
A panel of advisors to the Food and Drug Administration (FDA) rejected MDMA as a treatment for post-traumatic stress disorder (PTSD) on Tuesday, citing a lack of evidence that the benefits would outweigh the risks of introducing the psychedelic treatment to patients. Most stocks in the psychedelic space took a hit on Wednesday as a result of the ruling.The panel voted 9-2 that MDMA, when combined with talk therapy, is not effective in treating PTSD. The panel also voted 10-1 that the current benefits do not outweigh the potential risks of using the drug to treat mental issues.Some members of the panel, like sociologist Elizabeth Joniak-Grant, pointed to allegations of misconduct in trials th